News | October 07, 2025
IMCD unveils future of beauty at In-Cosmetics Latin America 2025
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs
Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
First-of-its-kind active cosmetic ingredient directly activates the oxytocin receptor, mimicking the dermatological effects of being in love
ANVIMO will be available in dosages of 240 mg and 480 mg
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
Subscribe To Our Newsletter & Stay Updated
